Mitsuya Ito
Hiroshima, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409).
Journal: Annals of surgical oncology
Published: October 28, 2025
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.
Journal: Breast cancer research and treatment
Published: September 12, 2025
Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis.
Journal: Breast cancer (Tokyo, Japan)
Published: March 05, 2025
Accumulation of CD56+ CD16- Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer.
Journal: World journal of oncology
Published: April 23, 2024
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Journal: Breast cancer research and treatment
Published: October 31, 2023
Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
Journal: Cancer medicine
Published: April 04, 2023
Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services.
Journal: JMA journal
Published: March 28, 2023
Outcomes in patients with non-invasive breast carcinoma.
Journal: Cancer reports (Hoboken, N.J.)
Published: September 14, 2022
Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
Journal: Japanese journal of clinical oncology
Published: February 15, 2022
Risk factors of local recurrence following implant-based breast reconstruction in breast cancer patients.
Journal: BMC women's health
Published: November 11, 2020
Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial.
Journal: World journal of oncology
Published: August 31, 2020
Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer.
Journal: Translational oncology
Published: May 13, 2020
Last Updated: 09/26/2026